Qyuns Therapeutics (HKG:2509) sold the global license to its QX027N drug to Windward Bio Group affiliate LE2025 Therapeutics, according to a Hong Kong bourse filing Monday.
The license covers all regions except mainland China, Taiwan, Hong Kong, and Macau.
Qyuns sold the license for payments totaling up to $700 million, including an upfront payment, an equity interest of Windward Bio, milestone payments, and royalties on the sales of the drug.
QX027N is being studied as a treatment for asthma and atopic dermatitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments